Steven O’Day, MD, Executive Director of the Saint John’s Cancer Institute and Cancer Clinic at Providence Saint John’s Health Center, and Director of Providence Los Angeles Regional Research, is the principal investigator for a phase 2 triple negative breast cancer study in collaboration with Biothera Pharmaceuticals. The findings of the study were highlighted in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on Saturday, June 1, 2019.
Biothera Pharmaceuticals, Inc. announced the primary data from IMPRIME 1, a Phase 2 clinical trial evaluating Imprime PGG, Biothera’s dectin receptor agonist, and KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc. (known as MSD outside the United States and Canada), in chemo-refractory metastatic triple negative breast cancer (mTNBC) patients.
“These early data suggest that Imprime PGG, which activates both the innate and adaptive immune response, in combination with anti-PD-1 immune checkpoint inhibitor therapy is a promising approach to cancer treatment, specifically triple negative breast cancer,” said Steven J. O’Day, M.D., the study’s principal investigator. “These data clearly support additional research for this therapeutic combination.”